-

Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign

  • This National Diabetes Awareness Month and World Diabetes Day, Dexcom is asking one simple question: If you could say anything to diabetes, what would you say?
  • Featuring voices from across the global diabetes community, including Nick Jonas, A Letter To Diabetes invites people to share their experiences and put into words everything they’ve wanted to say to diabetes.
  • Visit ALetterToDiabetes.com to explore stories from people impacted by diabetes around the world and submit your own letter.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today launched A Letter to Diabetes in honor of National Diabetes Awareness Month and World Diabetes Day, creating a platform for people around the world to put into words everything they’ve wanted to say about their diabetes journey, from the heartfelt and humorous to the hopeful and unexpected.

Throughout November, anyone touched by diabetes is invited to share their own letter to diabetes, including people living with the condition, caregivers, loved ones and healthcare professionals. Dexcom and voices from across the diabetes community will help bring these stories to a global stage, spotlighting the many different experiences of diabetes and creating a space for people to be seen and heard.

Together, these individual letters become something bigger: a celebration of the people, relationships and community that remind us that no one navigates diabetes alone. Because while diabetes may be part of someone’s story, it’s never their whole story.

Among those sharing their stories is multi-platinum recording artist, songwriter, actor and co-founder of Beyond Type 1 Nick Jonas, who has lived with type 1 diabetes for more than 20 years. In a deeply personal letter reflecting on his relationship with the condition, Jonas opens up about the challenges, lessons and emotions that have shaped his journey.

In an excerpt from his letter, Jonas writes:

“Diabetes, when we first met, your unpredictability threw me. I’d built my whole life around this unrealistic structure and belief that I was in control. You took that apart over the years, bit by bit. Part of me is grateful I learned that lesson. Part of me resents you for it. I never wanted to be a victim, or to come across like one. I share my story for the 13-year-old who just got diagnosed and is lying in a hospital bed, scared to death. I want them to see someone out there living their dreams while managing this, every single day.”

Across the diabetes community, strength takes many forms. From navigating the daily realities of diabetes to celebrating the small victories along the way. Chris Megino, who has built a supportive online social following, reflected on the lessons he’s learned throughout his 30-year journey with type 2 diabetes:

“Diabetes, if there’s anything you’ve taught me, it’s that strength isn’t about never struggling, it’s about showing up anyway. It’s the small wins. The workout you didn’t feel like doing. The better glucose reading. The family that supports you. So, diabetes, I’m not going to thank you for everything you put me through. But will thank you for teaching me something about myself and showing me I’m more capable than I thought.”

For others, the impact of diabetes extends beyond their own experience, shaping the lives of the people they love most. Chelsea Lugone, a nurse practitioner and diabetes care and education specialist at Dexcom who lives with type 1 diabetes and is the mother of two children who also have the condition, wrote:

“As much as you have shaped me, diabetes, I would give anything for you to disappear, especially from the lives of my children, Kate and Ryan. Living with diabetes is one thing, but watching my children live with it is something entirely different. For now, I will keep doing my best – for myself, for my children – leaning into our community and those who support us. I will continue to live the best life I can – reminding myself and others who are impacted by you that we are more than you – we are more than a number and we always will be.”

More than 589 million people worldwide live with diabetes1, and each has a story to share. To submit your letter to diabetes and explore stories from people impacted by diabetes around the world, visit ALetterToDiabetes.com.*

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

1 IDF Atlas, 11th edition (2025)

*Stories will be reviewed before posting, and while we value every submission, not all stories will be published

Contacts

Media Contact
Nadia Conard
mediarelations@dexcom.com

Investor Contact
Sean Christensen
sean.christensen@dexcom.com

DexCom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

Media Contact
Nadia Conard
mediarelations@dexcom.com

Investor Contact
Sean Christensen
sean.christensen@dexcom.com

More News From DexCom, Inc.

Dexcom Reports Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results...

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November

BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear,2 Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy,1 giving Canadians living with diabetes more time between sensor changes and...

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin. CONNECT participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%,...
Back to Newsroom